.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,166,219

« Back to Dashboard

Details for Patent: 5,166,219

Title: Systemic anti-inflammatory treatment
Abstract:A method of arthritis and other inflammatory diseases in humans or other mammals, comprising introducing into the circulatory system of the human or other mammal to be treated a composition consisting essentially of at least one C-27 to C-32 aliphatic alcohol in a physiologically compatible carrier is disclosed.
Inventor(s): Katz; David H. (La Jolla, CA)
Assignee: Lidak Pharmaceuticals (La Jolla, CA)
Filing Date:Jul 29, 1991
Application Number:07/737,492
Claims:1. A method of treating inflammatory disease in humans or other mammals, comprising introducing into the circulatory system of the human or other mammal in need of such treatment a physiologically effective amount of a composition consisting essentially of at least one C-27 to C-32 aliphatic alcohol in a physiologically compatible carrier.

2. The method of claim 1 wherein composition consists essentially of C-22 aliphatic alcohol in a physiologically compatible carrier comprising propylene oxide and ethylene oxide block co-polymer non-ionic detergent.

3. A method of treating inflammatory disease in humans or other mammals, comprising introducing into the circulatory system of the human or other mammal in need of such treatment by intramuscular injection a physiologically effective amount of a composition consisting essentially of at least one C-27 to C-32 aliphatic alcohol in a physiologically compatible carrier.

4. The method of claim 3 wherein composition consists essentially of C-22 aliphatic alcohol in a physiologically compatible carrier comprising propylene oxide and ethylene oxide block co-polymer non-ionic detergent.

5. A method of treating inflammatory disease in humans or other mammals, comprising introducing into the circulatory system of the human or other mammal in need of such treatment by trans-mucus membranal penetration a physiologically effective amount of a composition consisting essentially of at least one C-27 to C-32 aliphatic alcohol in a physiologically compatible carrier.

6. The method of claim 5 wherein composition consists essentially of C-22 aliphatic alcohol in a physiologically compatible carrier comprising propylene oxide and ethylene oxide block co-polymer non-ionic detergent.

7. A method of treating inflammatory disease in humans or other mammals, comprising introducing into the human or other mammal in need of such treatment by transdermal penetration a physiologically effective amount of a composition consisting essentially of at least one C-27 to C-32 aliphatic alcohol in a physiologically compatible carrier.

8. The method of claim 7 wherein composition consists essentially of C-22 aliphatic alcohol in a physiologically compatible carrier comprising propylene oxide and ethylene oxide block co-polymer non-ionic detergent.

9. A method of treating arthritis in humans or other mammals, comprising introducing into the circulatory system of the human or other mammal in need of such treatment a physiologically effective amount of a composition consisting essentially of at least one C-27 to C-32 aliphatic alcohol in a physiologically compatible carrier.

10. The method of claim 9 wherein composition consists essentially of C-22 aliphatic alcohol in a physiologically compatible carrier comprising propylene oxide and ethylene oxide block co-polymer non-ionic detergent.

11. A method of treating arthritis in humans or other mammals, comprising introducing into the circulatory system of the human or other mammal in need of such treatment by intramuscular injection a physiologically effective amount of a composition consisting essentially of at least one C-27 to C-32 aliphatic alcohol in a physiologically compatible carrier.

12. The method of claim 11 wherein composition consists essentially of C-22 aliphatic alcohol in a physiologically compatible carrier comprising propylene oxide and ethylene oxide block co-polymer non-ionic detergent.

13. A method of treating arthritis in humans or other mammals, comprising introducing into the circulatory system of the human or other mammal in need of such treatment by trans-mucus membrane penetration a physiologically effective amount of a composition consisting essentially of at least one C-27 to C-32 aliphatic alcohol in a physiologically compatible carrier.

14. The method of claim 13 wherein composition consists essentially of C-22 aliphatic alcohol in a physiologically compatible carrier comprising propylene oxide and ethylene oxide block co-polymer non-ionic detergent.

15. A method of treating arthritis in humans or other mammals, comprising introducing into the circulatory system of the human or other mammal in need of such treatment by transdermal penetration a physiologically effective amount of a composition consisting of at least one C-27 to C-32 aliphatic alcohol in a physiologically compatible carrier.

16. The method of claim 15 wherein composition consists essentially of C-22 aliphatic alcohol in a physiologically compatible carrier comprising propylene oxide and ethylene oxide block co-polymer non-ionic detergent.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc